Finance

Beta
Lists
Q2 2026 earnings • released • EPS beat +10.45% • Revenue beat +2.76%
See results
COO:NASDAQ
Cooper Companies Inc
$62.02
0.00%
(0.00) 1D
$65.86
+6.19% (+3.84)
Pre-market
Closed: Jun 4, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for COO...
Mkt. cap
12.10B
Avg. vol.
2.68M
Volume
26.02K
P/E ratio
52.39
52-wk high
$89.83
52-wk low
$58.89
EPS
$1.18
Beta
0.87
Shares outstanding
195.11M
No. of employees
15K
Mkt. cap
12.10B
Avg. vol.
2.68M
Volume
26.02K
P/E ratio
52.39
52-wk high
$89.83
52-wk low
$58.89
EPS
$1.18
Beta
0.87
Shares outstanding
195.11M
No. of employees
15K
Analyst outlook
Analyst Ratings
Based on 12 analysts giving stock ratings to COO in the past 3 months
Buy
Buy
6
Hold
5
Sell
1
12 month forecast
Based on 12 Wall Street analysts offering 12 month price targets for COO in the last 3 months.
Highest
Current $62.02
$103.00 (+66.08%)
Average
$84.50 (+36.25%)
Lowest
$61.00 (-1.64%)
News stories
From sources across the web
Profile
The Cooper Companies, Inc., branded as CooperCompanies, is a global medical device company headquartered in San Ramon, California. The company consists of two business units, CooperVision which manufactures contact lenses, and CooperSurgical, which manufactures medical devices and fertility and genomic products for the women's healthcare market. Wikipedia
About Cooper Companies Inc
CEOAlbert G. White III
Employees15K
Founded1958
HeadquartersPleasanton, California, United States
SectorMedical device
Websitecoopercos.com
Last report
Jun 4, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
$1.21 / $1.10
+10.45%beat
Revenue / Est. (USD)
1.08B / 1.05B
+2.76%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Apr 2025
Jul 2025
Oct 2025
Jan 2026
Revenue
1.00B
1.06B
1.07B
1.02B
Cost of goods sold
323.20M
368.30M
414.30M
328.90M
Cost of revenue
323.20M
368.30M
414.30M
328.90M
Research and development expenses
45.50M
44.60M
41.40M
44.30M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
399.00M
421.70M
415.40M
390.20M
Operating expense
494.30M
516.30M
506.60M
482.40M
Total operating expenses
817.50M
884.60M
920.90M
811.30M
Operating income
184.80M
175.70M
144.20M
212.80M
Other non operating income
800.00K
3.10M
-16.40M
3.10M
EBT including unusual items
144.50M
151.90M
116.80M
192.20M
EBT excluding unusual items
160.20M
151.90M
101.10M
192.20M
Income tax expense
56.80M
53.60M
32.20M
61.40M
Effective tax rate
39.31%
35.29%
27.57%
31.95%
Other operating expenses
-
-
-
-
Net income
87.70M
98.30M
84.60M
130.80M
Net profit margin
8.75%
9.27%
7.94%
12.77%
Earnings per share
0.96
1.10
1.15
1.10
Interest and investment income
-
-
-
-
Interest expense
-24.20M
-25.40M
-24.40M
-22.40M
Net interest expenses
-24.20M
-25.40M
-24.40M
-22.40M
Depreciation and amortization charges
-
-
-
-
EBITDA
277.40M
271.10M
242.60M
308.30M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer